ActiPatch(TM) Brand and Product Awareness On the Increase
FREDERICK, Md., July 15 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will resume airing an investment and product-related commercial on financial network Bloomberg Television. CEO of BioElectronics, Andrew Whelan says, "We previously ran this commercial in April with significant success relating both to our equity and product awareness. We are excited to see these commercials airing again today and reaching millions of people."
ActiPatch(TM), the product marketed by BioElectronics Corp. is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by MedicalHeadway.com, ActiPatch(TM) is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.
ActiPatch(TM) is a drug-free wafer thin patch with an embedded battery- operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.
ActiPatch(TM) is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery.
Distribution has expanded into Canada, Italy, Switzerland, Denmark, Scandinavian countries, Singapore, Malaysia and India.
For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.
About BioElectronics Corporation
BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch(TM) is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.
Information on ActiPatch(TM) and BioElectronics Corporation is
available at the following websites:
-- U.S. Consumer: http://www.actipatchonline.com
-- Podiatry: http://www.pemfpodiatry.com
-- German orthopedic foot & ankle: http://www.diesfussexperten.de
-- Italy and Switzerland: http://www.actipatch.it
-- Canada: http://www.actipatchpaintherapy.ca
-- Netherlands: http://www.actipatch.de
-- Singapore & Malaysia: http://www.astonixlife.com/
-- BioElectronics Corp: http://www.bioelectronicscorp.com
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management in light of current
conditions, expected future developments and other factors it believes to
be appropriate. Actual results may differ as a result of factors over which
the company has no control.
Media Relations Contact:
Patricia Baker, The Big Picture Agency LLC
Voice: 413-623-0950 ext. 221, email: email@example.com
Investor Relations Contact:
Joe Noel, Emerging Growth Research LLP
Voice: 925-922-2560, email: firstname.lastname@example.org
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved